- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05282433
Surufatinib Alone or Combined With Anti-PD-1 mAb in the Treatment of Advanced Hepatocellular Carcinoma
Surufatinib Alone or Combined With Anti-PD-1 mAb in the Treatment of Advanced Hepatocellular Carcinoma:HCCSC C01 Trial
Study Overview
Status
Intervention / Treatment
Detailed Description
This is an open, prospective, single-arm, multi-cohort clinical study to evaluate the efficacy and safety of surufatinib alone or combined with Anti-PD-1 mAb in the treatment of advanced Hepatocellular Carcinoma.
Cohort A: patients with advanced hepatocellular carcinoma who had failed previous standard first-line therapy and could not tolerate or reject existing therapies.Treatment:surufatinib combined with Anti-PD-1 mAb Cohort B: patients with advanced pancreatic cancer who had previously failed standard sencond-line therapy, could not tolerate or reject existing therapies.Treatment:surufatinib alone.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Fuxiang Zhou, MD,PhD
- Phone Number: +86-027-67813155
- Email: fuxiang.zhou@whu.edu.cn
Study Locations
-
-
Hubei
-
Wuhan, Hubei, China, 430070
- Recruiting
- Zhongnan Hopital of Wuhan University
-
Contact:
- Fuxiang Zhou, MD
- Phone Number: +86-027-67813155
- Email: fuxiang.zhou@whu.edu.cn
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 1. 18 years to 75 years. 2.Had a disease status that was measurable or evaluable as defined by Response Evaluation Criteria in Solid Tumors (RECIST, version1.1): Cohort A: patients with advanced hepatocellular carcinoma who had failed previous standard first-line therapy and could not tolerate or reject existing therapies.
Cohort B: patients with advanced hepatocellular carcinoma who had previously failed standard sencond-line therapy, could not tolerate or reject existing therapies.
3.Adequate hepatic, renal, heart, and hematologic functions (hemoglobin ≥80g/L, platelets ≥ 80×10^9/L, neutrophils ≥ 1.5×10^9/L, total bilirubin within 1.5×the upper limit of normal(ULN), ALT and AST≤2.5×the ULN (If liver metastases, serum transaminase≤5×the ULN), serum creatine ≤ 1.5 x ULN, creatinine clearance rate > 50ml/min).
4.At least 4 weeks after the last anti-tumor treatment (surgery, chemotherapy, radiotherapy, biotherapy or endocrine therapy) before enrollment.
5.Had a life expectancy of at least 3 months. 6.Had an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0, 1, or 2.
7.Signed informed consent.
Exclusion Criteria:
1.In the past or at the same time with other malignant tumors (already cure period of IB or cervical, lower levels of noninvasive basal cell or squamous cell cancer, obtain complete remission (CR) > 10 years of breast cancer, obtain complete remission (CR) > 10 years of malignant melanoma, obtain complete remission (CR) > 5 years except of other malignant tumors).
2.Pregnant or lactating female patients. 3.Had a history of clinically significant or uncontrolled heart disease, including but not limited to: (1)Myocardial infarction. (2)Angina.(3)Congestive heart failure above grade 2 of the New York heart association (NYHA).(4)Ventricular arrhythmias requiring continuous treatment.(5)Supraventricular arrhythmias, including uncontrolled atrial fibrillation.
4.The patients had mental disorders, and the researchers believed that the patients could not fully or fully understand the possible complications in this study.
5.Have a history of immunodeficiency, including: HIV positive, or other acquired or congenital immunodeficiency diseases, or a history of organ transplantation.
6.Those who cannot tolerate or may be allergic to the drugs used in this study. 7.Participated in clinical trials of other drugs within the past 1 month. 8.Other factors considered unsuitable for the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Research Group
Patients with advanced hepatocellular carcinoma who had failed previous standard 1/2-line therapy and could not tolerate or reject existing therapies.
|
Surufatinib Alone or Combined With Anti-PD-1 mAb in the Treatment of Advanced Hepatocellular Carcinoma
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression-free survival
Time Frame: up to 12 weeks
|
Progression-free survival
|
up to 12 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Fuxiang Zhou, MD,PhD, Wuhan University
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HCCSC H01
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hepatocellular Carcinoma; Targeted Therapy; Progression-free Survival
-
The First Affiliated Hospital of Xiamen UniversityNot yet recruitingProgression-free Survival;Progression-free Survival;Disease Control Rate; SafetyChina
-
Chinese PLA General HospitalCompletedCost | Overall Survival | Progression-free Survival
-
Grupo Hospital de MadridCompletedProgression Free SurvivalSpain
-
Peking UniversityCompletedProgression Free Survival of the TreatmentChina
-
University of MilanUnknownOverall Survival | Patients Affected by Hepatocellular Carcinoma | Disease-Free SurvivalItaly
-
AstraZenecaCompletedProgression-free SurvivalKorea, Republic of
-
Fuda Cancer Hospital, GuangzhouCompletedProgress Free Survival (PFS) and Overall Survival (OS)China
-
Qinghai Red Cross HospitalRecruitingAdvanced Cancer | Progression Free Survival | OlanzapineChina
-
Tianjin Medical University Cancer Institute and...Not yet recruitingProgression Free Survival(PFS)
-
Laibin People's HospitalCompletedThe Primary Study Metric is Progression-free Survival (PFS)
Clinical Trials on Surufatinib
-
The Affiliated Hospital of Xuzhou Medical UniversityRecruiting
-
Qilu Hospital of Shandong UniversityThe Affiliated Hospital of Qingdao University; Shandong Provincial Hospital... and other collaboratorsNot yet recruitingNeuroendocrine Tumor Grade 3
-
Qilu Hospital of Shandong UniversityNot yet recruiting
-
Hutchison Medipharma LimitedCompletedHealthyUnited States
-
Shanghai Ninth People's Hospital Affiliated to...RecruitingHead and Neck Cancers - Salivary GlandChina
-
Zhejiang Cancer HospitalRecruitingBile Duct AdenocarcinomaChina
-
Changhai HospitalNot yet recruitingPancreatic Neuroendocrine TumorChina
-
Sun Yat-sen UniversityRecruiting
-
The Affiliated Nanjing Drum Tower Hospital of Nanjing...RecruitingHepatocellular CarcinomaChina
-
Sun Yat-sen UniversityRecruiting